Explore 3 Stock Ideas & Industry Insights Download Free Report

Zenith Capital Corp

Company price
0.03 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
2101
Market Cap
7.99M

Momentum Score

…

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.03
Low
0.05
High
52 Week Price Range
0.00
Low
0.19
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information for Zenith Capital Corp (ZHCLF.US) on the Pink market is limited, so the company's core business, assets and financial condition are not clearly documented. Long-term prospects therefore depend on management clarifying strategy, access to capital and verified operating results; investors may find upside if substantive disclosures are published.
Key risks include limited disclosure, extremely low trading liquidity, uncertain governance and financial transparency, and increased potential for dilution, volatility or delisting.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.03
Dividend Yield
-
Revenue TTM
0.50M
Revenue Per Share
0.00
Gross Profit TTM
0.50M
Debt / Equity
-0.51
ROE
-
Net Debt
0.01M
ROCE
72190.30%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Type yearly yearly yearly yearly yearly
Date 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Income before tax -7.92M -7.32M -10.56M - -7.77M
Net income -7.94M -7.35M -10.60M - -7.80M
Selling general administrative 2.07M 1.92M 2.21M - 3.33M
Gross profit - 0.50M - - -
Reconciled depreciation - - - - 0.19M
Ebit -3.14M -4.73M -8.77M -11.16M -7.38M
Ebitda -3.02M -4.63M -8.61M - -7.31M
Depreciation and amortization 0.12M 0.10M 0.16M - -
Operating income -3.20M -4.79M -8.94M - -7.38M
Other operating expenses 3.20M 5.29M 8.94M - -
Interest expense - 1.58M - - 0.27M
Tax provision - - - - 0.03M
Net interest income - - - - -0.51M
Income tax expense 0.02M 0.03M 0.03M 0.02M 0.03M
Total revenue - 0.50M - - 0.00M
Total operating expenses 3.20M 5.29M 8.94M - 7.38M
Total other income expense net -4.72M -2.52M -1.62M - 0.12M
Net income from continuing ops - - - - -7.80M
Net income applicable to common shares - - - -13.12M -7.80M
Breakdown 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Type yearly yearly yearly yearly yearly
Date 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total assets - - 0.01M - 2.88M
Intangible assets - - 0.00M - 0.88M
Other current assets - - 0.01M 0.06M 0.01M
Total liab - - 0.03M - 16.72M
Total stockholder equity - - -0.02M - -13.84M
Deferred long term liab - - - 0.70M 0.71M
Other current liab - - 0.01M 0.17M 0.08M
Common stock - - 0.09M 89.62M 80.94M
Capital stock - - - - 80.94M
Retained earnings - - -0.13M -118.36M -105.24M
Other liab - - - 11.35M 11.35M
Other assets - - - 0.70M 0.77M
Cash - - 0.00M - 0.01M
Total current liabilities - - 0.01M 6.68M 5.36M
Current deferred revenue - - 0.00M - -
Net debt - - 0.01M - 3.47M
Short term debt - - 0.01M - -
Short long term debt - - - - 3.48M
Short long term debt total - - 0.01M - -
Other stockholder equity - - 0.01M 2.14M 0.81M
Property plant equipment - - - 0.10M 0.22M
Total current assets - - 0.01M 1.38M 1.00M
Net tangible assets - - - -15.86M -14.72M
Net receivables - - 0.00M 1.16M 0.16M
Inventory - - 0.00M 0.11M 0.30M
Accounts payable - - 0.00M 2.07M 1.65M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other - - 0.00M - 0.76M
Non current assets total - - 0.00M - 1.88M
Breakdown 2024-04-30 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly yearly yearly
Date 2024-04-30 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Investments - - -0.26M -0.25M -0.37M
Change to liabilities - 0.34M 3.48M -1.78M 6.40M
Total cashflows from investing activities -0.00M -0.17M -0.26M -0.25M -0.37M
Net borrowings - 1.02M 0.72M 2.68M 0.59M
Total cash from financing activities 0.01M 9.28M 1.10M 7.97M 3.11M
Change to operating activities - -0.63M 0.18M -0.61M -0.42M
Net income -0.01M -13.12M -7.80M -6.91M -9.63M
Change in cash 0.00M 0.02M 0.00M -0.21M 0.01M
Begin period cash flow 0.00M 0.01M 0.01M 0.21M 0.21M
End period cash flow 0.00M - 0.01M 0.01M 0.21M
Total cash from operating activities -0.00M -9.08M -0.85M -7.93M -2.73M
Issuance of capital stock - - 0.48M 5.45M 2.50M
Depreciation 0.00M 0.20M 0.19M 0.19M 0.21M
Other cashflows from investing activities -0.00M 0.02M -0.09M 0.07M -0.05M
Dividends paid - - 0.00M 0.00M 0.00M
Change to inventory 0.00M 0.26M 0.30M 0.04M -0.00M
Other cashflows from financing activities 0.00M -0.19M -0.14M -0.17M -0.02M
Change to netincome - 3.87M 2.79M 1.16M 0.70M
Capital expenditures 0.00M 0.00M 0.16M 0.32M 0.01M
Change in working capital 0.00M - 3.97M -2.36M 6.49M
Stock based compensation 0.00M - 2.33M 1.01M 0.55M
Other non cash items 0.00M - 0.34M 0.07M -1.37M
Free cash flow -0.00M - -1.01M -8.25M -3.05M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ZHCLF
Zenith Capital Corp
-
-%
0.03 - - 54.31 - -1.36
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Zenith Capital Corp

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.

4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1

587 390 7865

Name Title Year Born
Mr. Donald J. McCaffrey Chairman, Pres & CEO NA
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV CFO & Sec. NA
Dr. Sanjay Lakhotia M.B.A., Ph.D. Chief Bus. Officer NA
Dr. Henrik Claus Hansen Ph.D. Sr. VP of Operations NA
Dr. Huan Zhu Chief Medical Officer NA
Mr. Donald J. McCaffrey Chairman, President & CEO NA
Mr. Aaron Bradley Cann C.A., CPA, CBV CFO & Secretary NA
Dr. Sanjay Lakhotia M.B.A., Ph.D. Chief Business Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…